-
Product Insights
Relapsing Remitting Multiple Sclerosis (RRMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Relapsing Remitting Multiple Sclerosis (RRMS) - Drugs In Development, 2023’, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Drugs In Development, 2023’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Dermatological Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Dermatological Disorders - Drugs In Development, 2023’, provides an overview of the Dermatological Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dermatological Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
Contract Pharmaceutical Dose Manufacturing Industry – Composition, Size, Market Share and Outlook, 2023 Edition
Contract Pharmaceutical Dose Manufacturing Industry Overview The total dose CMO contract revenue in 2022 represented significant growth over 2021 revenue. The growth rate was the highest recorded since 2011 for commercial contract dose manufacturing revenues, and surprisingly adds to the strong growth experienced in 2021, despite demand for COVID-19 vaccines and therapies waning in 2022. The Contract Pharmaceutical Dose Manufacturing Industry report is a comprehensive look at the finished dose contract manufacturing landscape in 2023. It includes an analysis of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vedolizumab Biosimilar in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vedolizumab Biosimilar in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vedolizumab Biosimilar in Ulcerative Colitis Drug Details: Vedolizumab biosimilar (PB-016) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Bone Metastasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Denosumab Biosimilar in Bone Metastasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Denosumab Biosimilar in Bone MetastasisDrug Details:Denosumab (JHL-1266) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegfilgrastim in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegfilgrastim in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Pegfilgrastim in Breast CancerDrug Details: Pegfilgrastim (Nyvepria, Pegneucyte) is a covalent conjugate of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Kid EDV in Pediatric Diffuse Intrinsic Pontine Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Kid EDV in Pediatric Diffuse Intrinsic Pontine Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Kid EDV in Pediatric Diffuse Intrinsic Pontine GliomaDrug Details:Kid...
-
Company Profile
Polpharma SA – Company Profile
Polpharma SA (Polpharma), a subsidiary Genefar BV, undertakes research activities, manufacturing, and marketing of prescription drugs, generic drugs, hospital drugs, dietary supplements, medical equipment, and over-the-counter medications. It provides drugs in therapeutic areas of cardiology, anti-infectives, gastroenterology, neurology, dermatology, pulmonary, and ophthalmology areas. The company also manufactures dietary supplements and medical devices. The company undertakes operations in Central and Eastern Europe, the Caucasus and Central Asia markets, and production plants in Russia, Kazakhstan, and Poland. Polpharma group includes Santo; Medana...
Add to Basket -
Product Insights
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Integrin Beta 7 Pipeline Drugs Market Report Overview Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1, which is normally expressed by the vascular endothelium of the gastrointestinal tract. The Integrin Beta 7 pipeline drugs market research report provides comprehensive information on the Integrin Beta 7 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report...